|
Bayer acquires HiDoc Technologies and Cara Care® app for irritable bowel syndrome
|
11 December 2024 |
|
Bayer Foundation announces Science Awards winners of 2024
|
06 November 2024 |
|
Bayer and Dewpoint Therapeutics sign licensing agreement for heart disease program
|
25 October 2024 |
|
Bayer submits EU marketing authorization application for elinzanetant to treat moderate to severe vasomotor symptoms
|
15 October 2024 |
|
BlueRock Therapeutics' investigational cell therapy bemdaneprocel for Parkinson's disease shows positive data at 24-months
|
30 September 2024 |
|
Bayer Co.Lab Shanghai opens as part of global expansion of life science incubator network
|
26 September 2024 |
|
Bayer and NextRNA Therapeutics enter strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in oncology
|
30 August 2024 |
|
Vividion Therapeutics to expand with new global research and development center
|
01 August 2024 |
|
Darolutamide meets primary endpoint in Phase III ARANOTE trial
|
17 July 2024 |
|
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson's disease
|
11 July 2024 |
|
Berlin Center for Gene and Cell Therapies kicked off in Berlin
|
25 June 2024 |
|
Bayer receives Breakthrough Therapy designation in China for BAY 2927088
|
18 June 2024 |
|
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate bemdaneprocel
|
30 May 2024 |
|
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
|
25 April 2024 |
|
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson's disease
|
16 April 2024 |
|
Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines
|
20 March 2024 |
|
Bayer and Aignostics to collaborate on next generation precision oncology
|
15 March 2024 |
|
Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations
|
27 February 2024 |
|
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
|
15 February 2024 |
|
Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor
|
07 February 2024 |